Research Topics
Species | John BilezikianSummaryAffiliation: Columbia University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safetyNatalie E Cusano
Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 98:137-44. 2013..PTH may be an effective treatment option for hypoparathyroidism, but long-term data are not available...- Normocalcemic primary hyperparathyroidismJohn P Bilezikian
Departamento de Medicina, Columbia University, NY, NY, USA
Arq Bras Endocrinol Metabol 54:106-9. 2010..In this article, we describe this new entity, normocalcemic primary hyperparathyroidism, a forme fruste of the disease... 
Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosisJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, New York, NY 10032, USA
Curr Osteoporos Rep 4:5-13. 2006..To maintain the gains in bone density with PTH, it is important to follow its use with an antiresorptive agent...- Parathyroid hormone as an anabolic therapy for women and menJ P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
J Endocrinol Invest 28:41-9. 2005..In order to maintain the densitometric gains in bone density with parathyroid hormone, it is important to follow its use with an antiresorptive agent... - Anabolic therapy for osteoporosisJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032 USA
Womens Health (Lond Engl) 3:243-53. 2007..Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents has led to ways in which the anabolic window can be expanded... - Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic windowJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA E mail
Curr Osteoporos Rep 6:24-30. 2008..Newer approaches to the use of teriparatide alone and in combination with antiresorptive agents have led to ways in which the anabolic window can be expanded... - Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshopJohn P Bilezikian
Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
J Clin Endocrinol Metab 94:335-9. 2009..CONSENSUS PROCESS: Consensus was achieved by a group meeting. Statements were prepared and reviewed by all authors who represented the Planning Committee and the participating professional societies... - Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical featuresJ P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
J Intern Med 257:6-17. 2005..At the NIH workshop, a number of items were highlighted for further investigation such as pharmacological approaches to controlling hypercalcaemia, elevated PTH levels and maintaining bone density... 
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosisJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Am J Med 122:S14-21. 2009..Clinical trial extensions of up to 10 years with alendronate and 7 years with risedronate have shown that efficacy is maintained during long-term treatment...- Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st centuryJohn P Bilezikian
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Clin Endocrinol Metab 87:5353-61. 2002 - Asymptomatic primary hyperparathyroidismJohn P Bilezikian
Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Arq Bras Endocrinol Metabol 50:647-56. 2006..In this article, we will review important clinical and diagnostic features of asymptomatic primary hyperparathyroidism as well as considerations for surgical or medical management of the disease... - Circulating sclerostin in disorders of parathyroid gland functionAline G Costa
Department of Medicine, Division of Endocrinology, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 96:3804-10. 2011..Sclerostin, a protein encoded by the SOST gene in osteocytes and an antagonist of the Wnt signaling pathway, is down-regulated by PTH administration. Disorders of parathyroid function are useful clinical settings to study this relationship... - Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future researchJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
J Bone Miner Res 26:2317-37. 2011..This review, which focuses primarily on hypoparathyroidism in the adult, provides a comprehensive summary of the latest information on this disease... - Regulation of bone mass by serotonin: molecular biology and therapeutic implicationsGerard Karsenty
Department of Genetics and Development, Columbia University Medical Center, New York, New York 10032, USA
Annu Rev Med 62:323-31. 2011..Exploiting these findings in the pharmacological arena led to the demonstration that inhibiting synthesis of gut-derived serotonin could be an effective means to treat low-bone-mass diseases such as osteoporosis... - Clinical practice. Asymptomatic primary hyperparathyroidismJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York 10032, USA
N Engl J Med 350:1746-51. 2004 - The potential of parathyroid hormone as a therapy for osteoporosisMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Int J Fertil Womens Med 47:103-15. 2002..In all studies reported to date, PTH appears to be well tolerated. The era of anabolic therapy for osteoporosis is at hand, with PTH being the first to be tested with sufficient rigor to demonstrate its efficacy... - Anabolic skeletal therapy for osteoporosisMonica Girotra
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Arq Bras Endocrinol Metabol 50:745-54. 2006..Other potential anabolic therapies for osteoporosis, including other forms of parathyroid hormone, strontium ranelate, growth hormone, and insulin-like growth factor-1, are also reviewed in this article... - Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosisDiana M Antoniucci
Division of Endocrinology, Department of Medicine, University of California, San Francisco, California 94107, USA
J Clin Endocrinol Metab 92:942-7. 2007..The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated... - Anabolic therapy for osteoporosisJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Int J Fertil Womens Med 50:53-60. 2005..This paper describes the activities as known at present of the bisphosphonates and of teriparatide and reviews studies of their use alone and in combination with each other... - Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorderSUSAN THYS-JACOBS
St Luke s Roosevelt Hospital Center, Columbia University, New York, New York 10019, USA
J Clin Endocrinol Metab 92:2952-9. 2007..Recently, it has been suggested that abnormalities in calcium metabolism may be responsible for some affective and somatic symptoms in women with premenstrual syndrome... - Alendronate increases bone mass and reduces bone markers in postmenopausal African-American womenNorman H Bell
Department of Medicine, Bone, and Mineral Metabolism, Medical University of South Carolina, 114 Doughty Street, PO Box 250775, Charleston, SC 29425, USA
J Clin Endocrinol Metab 87:2792-7. 2002..We conclude that in postmenopausal African-American women with osteoporosis, alendronate, 10 mg daily for 2 yr, increases BMD at the lumbar spine, hip, and total body and reduces markers of bone remodeling and is well tolerated... - New anabolic therapies in osteoporosisMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Curr Opin Rheumatol 14:433-40. 2002..Of these, parathyroid hormone has clearly emerged as the most promising treatment at this time... - Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidismMunro Peacock
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
J Clin Endocrinol Metab 90:135-41. 2005..Cinacalcet rapidly normalizes serum calcium and reduces PTH in patients with primary HPT, and these effects are maintained with long-term treatment. Cinacalcet may be an effective, nonsurgical approach for management of primary HPT... - The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 yearsMishaela R Rubin
Department of Medicine, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032, USA
J Clin Endocrinol Metab 93:3462-70. 2008..We previously reported that calciotropic indices and bone mineral density (BMD) are stable in untreated patients for up to a decade, whereas after parathyroidectomy, normalization of biochemistries and increases in BMD ensue... - Clinical review: Rare causes of hypercalcemiaThomas P Jacobs
Columbia University Medical Center, 161 Fort Washington Avenue, New York, New York 10032, USA
J Clin Endocrinol Metab 90:6316-22. 2005..This review considers unusual causes of hypercalcemia that are generally not found in reviews on this subject... - Parathyroid hormone as an anabolic skeletal therapyMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Drugs 65:2481-98. 2005..However, in order to maintain the densitometric gains in bone density obtained with PTH, it is important to follow its use with that of an antiresorptive agent... - The diagnosis and management of asymptomatic primary hyperparathyroidismShonni J Silverberg
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Nat Clin Pract Endocrinol Metab 2:494-503. 2006.... - The use of parathyroid hormone in the treatment of osteoporosisMonica Girotra
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 W. 168th Street, New York, NY 10032, USA
Rev Endocr Metab Disord 7:113-21. 2006..In order to maintain increases in bone density acquired during PTH therapy, it is important to follow its use with an antiresorptive agent... - Human chorionic gonadotropin measurements in parathyroid carcinomaMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York 10032, USA
Eur J Endocrinol 159:469-74. 2008..We investigated whether hCG can distinguish PtCa cancer from benign disease and add prognostic information... - Dynamic and structural properties of the skeleton in hypoparathyroidismMishaela R Rubin
College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Bone Miner Res 23:2018-24. 2008..032 +/- 0.028 microm(3)/microm(2)/d, p < 0.0001), were profoundly suppressed in the hypoparathyroid subjects. We conclude that hypoparathyroidism is characterized by markedly unusual structural and dynamic properties of bone... - Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fracturesEthel S Siris
Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 88:3482-6. 2003..A call to action is necessary to reduce the human and economic costs associated with this serious and treatable disease... - Application of high-resolution skeletal imaging to measurements of volumetric BMD and skeletal microarchitecture in Chinese-American and white women: explanation of a paradoxMARCELLA D WALKER
Columbia University, College of Physicians and Surgeons, New York, New York, USA
J Bone Miner Res 24:1953-9. 2009..Using the high-resolution technology, the results provide a mechanistic explanation for why Chinese women have fewer hip and forearm fractures than white women... - Cystosarcoma phyllodes of the breast occurring in a child with subsequent diagnosis of celiac diseaseGovind Bhagat
Department of Surgical Pathology and Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Pediatr Gastroenterol Nutr 36:644-6. 2003 - New anabolic therapies in osteoporosisMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
Endocrinol Metab Clin North Am 32:285-307. 2003..Rising expectations that anabolic therapies for osteoporosis will soon play a major role in treating this disease are likely to fuel further studies and the development of even more novel approaches to therapy... - Age as a criterion for surgery in primary hyperparathyroidismShonni J Silverberg
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Am J Med 113:681-4. 2002 - Bone markers--new aspectsSerge Cremers
Department of Medicine, Endocrinology, Columbia University, New York, NY 10032, USA
Clin Lab 54:461-71. 2008..This review discusses some of these new aspects in a perspective that has utility for clinical studies and individual patient care... - Asymptomatic primary hyperparathyroidism: new issues and new questions--bridging the past with the futureJohn P Bilezikian
Department of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Bone Miner Res 17:N57-67. 2002..helpful and cost effective to warrant their use in all patients who undergo parathyroid surgery? If not, in what patients should they be recommended? (7) What items should be placed on the research agenda for PHPT over the next decade?.. - Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st centuryJohn P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Bone Miner Res 17:N2-11. 2002 - Three dimensional cancellous bone structure in hypoparathyroidismMishaela R Rubin
Metabolic Bone Diseases Unit, Department of Medicine, College of Physicians and Surgeons, Columbia University New York, NY, USA
Bone 46:190-5. 2010..The effect of these structural changes on bone strength remains to be determined... - Asymptomatic primary hyperparathyroidism: a medical perspectiveShonni J Silverberg
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
Surg Clin North Am 84:787-801. 2004..These guidelines are elucidated, and new options in the medical therapeutics of primary hyperparathyroidism are discussed... - Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidismShonni J Silverberg
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 88:4725-30. 2003..This study also provides evidence that both PTH (1-84) and PTH fragments are produced in parathyroid adenomas and that peripheral metabolism of hormone and fragment does not alter the proportion of bioactive hormone... - "Incipient" primary hyperparathyroidism: a "forme fruste" of an old diseaseShonni J Silverberg
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 88:5348-52. 2003.... - The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]Etah S Kurland
Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, PH 8 West 864, New York, NY 10032, USA
Osteoporos Int 15:992-7. 2004..The immediate use of bisphosphonates after teriparatide withdrawal may help to optimize gains in bone density at the lumbar spine... - Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidismEmily M Stein
College of Physicians and Surgeons, Columbia University, New York, NY, USA
Bone 48:557-61. 2011..Vitamin D deficiency is common in patients with primary hyperparathyroidism (PHPT). The presence of low levels of vitamin D may affect the skeletal consequences of PHPT... - The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidismDolores M Shoback
Department of Medicine, Veterans Affairs Medical Center, University of California San Francisco, San Francisco, California 94121, USA
J Clin Endocrinol Metab 88:5644-9. 2003.... - An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinomaMishaela R Rubin
College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Clin Chem 53:1470-6. 2007..We investigated whether N-PTH is also overproduced in parathyroid cancer and whether N-PTH concentration is influenced by calcimimetic therapy... - Idiopathic osteoporosis in premenopausal womenMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, N.Y. 10032, USA
Osteoporos Int 16:526-33. 2005..4+/-1.6 ng/ml versus 14.7+/-0.8 ng/ml), although the difference was not statistically significant. These results suggest differences in the pathogenesis of idiopathic osteoporosis in women as compared to men with IOP... - The anabolic effects of parathyroid hormone therapyMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
Clin Geriatr Med 19:415-32. 2003..Ultimately, when the anabolic and catabolic mechanisms of PTH can be clearly distinguished, both mechanistically and in molecular terms, it may be possible to develop PTH analogs that are more purely anabolic... - Lower insulin-like growth factor-1 concentrations in women with premenstrual dysphoric disorderSUSAN THYS-JACOBS
Division of Endocrinology, Department of Medicine, St Luke s Roosevelt Hospital, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA
Am J Obstet Gynecol 198:506.e1-8. 2008..Our objective was to measure the cyclic variations in bone turnover across the menstrual cycle in women with and without luteal phase symptoms consistent with severe premenstrual syndrome or premenstrual dysphoric disorder... - Osteoporosis in men: pathophysiology and treatmentLuigi Gennari
College of Physicians and Surgeons, 630 W 168th Street, New York, NY 10032, USA
Curr Rheumatol Rep 9:71-7. 2007..This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men... - Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administrationMami Ogita
Department of Medicine, Columbia University, New York, New York 10032, USA
Endocrinology 149:5713-23. 2008..Estrogens promote proliferation of early osteoblast progenitors but inhibit their differentiation by osteogenic agents such as PTH or BMP-2... - Race and diet interactions in the acquisition, maintenance, and loss of boneMARCELLA D WALKER
Division of Endocrinology, Metabolic Bone Disease Unit, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
J Nutr 138:1256S-60S. 2008..Predictors of aBMD have been reported for African American and American white adults and predictors of aBMD in Chinese American women have recently been studied. Much remains to be studied regarding interactions between race and diet... - Osteonecrosis of the jaw--do bisphosphonates pose a risk?John P Bilezikian
College of Physicians and Surgeons, Columbia University, New York, USA
N Engl J Med 355:2278-81. 2006 - Arterial stiffness in mild primary hyperparathyroidismMishaela R Rubin
Columbia University, College of Physicians and Surgeons, Department of Medicine, PH8-864, 630 West 168th Street, New York, New York 10032, USA
J Clin Endocrinol Metab 90:3326-30. 2005..05). The diagnosis of primary hyperparathyroidism was therefore an independent predictor of increased AIx, an early measure of arterial stiffness, and the increase was associated with evidence of more active parathyroid disease... - The role of estrogens in men and androgens in womenSundeep Khosla
Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, 5 194 Joseph, Rochester, MN 55905, USA
Endocrinol Metab Clin North Am 32:195-218. 2003.... - Racial differences in the effect of early milk consumption on peak and postmenopausal bone mineral densityAlexander R Opotowsky
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Bone Miner Res 18:1978-88. 2003..CONCLUSION: The results show racial differences in the effect of early milk consumption on peak and postmenopausal bone mineral density... - Standards for performing DXA in individuals with secondary causes of osteoporosisAliya A Khan
Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
J Clin Densitom 9:47-57. 2006..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis... - Bone density in survivors of childhood cancerJean E Mulder
Department of Medicine, College of Physicians and Surgeons, New York, NY, USA
J Clin Densitom 7:432-42. 2004..After a brief review of the processes associated with acquisition of peak bone mass in the young adult, this article examines the impact of cancer and cancer therapy on bone mineral density in survivors of childhood cancer... - Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidenceMishaela R Rubin
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 87:4033-41. 2002 - Vitamin D toxicity due to a commonly available "over the counter" remedy from the Dominican RepublicHyesoo Lowe
Division of Endocrinology, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032, USA
J Clin Endocrinol Metab 96:291-5. 2011..Hypercalcemia in ambulatory patients is occasionally caused by vitamin D toxicity... - High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial boneX Sherry Liu
Bone Bioengineering Laboratory, Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
J Bone Miner Res 25:746-56. 2010..We conclude that microstructural measurements and mechanical parameters of distal tibia can be efficiently derived from HR-pQCT images and provide additional information regarding bone fragility... - The cell biology of parathyroid hormone in osteoblastsStavroula Kousteni
Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
Curr Osteoporos Rep 6:72-6. 2008..PTH's ability to orchestrate a dynamic range of signaling cascades that determine osteoblast fate may explain both its catabolic and beneficial actions on the skeleton... - Summary of the International Society For Clinical Densitometry 2005 Position Development ConferenceNeil Binkley
Department of Medicine, University of Wisconsin, Madison, WI 53705, USA
J Bone Miner Res 22:643-5. 2007 - When should a gynecologist refer a patient for specialty care in osteoporosis?John P Bilezikian
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Int J Fertil Womens Med 48:132-6; discussion 137-8. 2003.... - Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up studyAlexander R Opotowsky
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Am J Med 117:169-74. 2004..1 to 3.3) and highest (HR = 2.1; 95% CI: 1.2 to 3.6) quintiles compared with those in the middle quintiles. CONCLUSION: Both low and high serum vitamin A concentrations may be associated with an increased risk of hip fracture... - Osteoporosis in men: pathophysiology and treatmentLuigi Gennari
College of Physicians and Surgeons, 630 W 168th Street, New York, NY 10032, USA
Curr Osteoporos Rep 5:22-8. 2007..This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men... - PTH-dependent adenylyl cyclase activation in SaOS-2 cells: passage dependent effects on G protein interactionsHong Gao
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA
J Cell Physiol 193:10-8. 2002..The results suggest that the coupling between the components of the complex may be pivotally important in the differential responsiveness of early and late passage SaOS-2 cells to PTH... - Clinical use of teriparatide in the real world: initial insightsPaul D Miller
Colorado Center for Bone Research, Lakewood, 80227, USA
Endocr Pract 10:139-48. 2004..This manuscript is a compendium of the consensus opinions of the authors that attempts to provide practical answers to many real-world questions being asked about teriparatide therapy since its approval by the FDA... - Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trialAliya A Khan
McMaster University, 331 209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8
J Clin Endocrinol Metab 89:3319-25. 2004..Significant reductions in bone turnover occur with stable serum calcium and PTH levels. Alendronate may be a useful alternative to parathyroidectomy in asymptomatic PHPT among those with low BMD... - Sex steroids, mice, and men: when androgens and estrogens get very close to each otherJohn P Bilezikian
J Bone Miner Res 17:563-6. 2002 - Glucocorticoid-induced osteoporosis: an updateGherardo Mazziotti
Department of Internal Medicine, Spedali Civili, University of Brescia, 25125 Brescia, Italy
Trends Endocrinol Metab 17:144-9. 2006..Anabolic and alternative therapeutic strategies are currently under investigation in glucocorticoid-induced osteoporosis... - The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisDennis M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94105, USA
N Engl J Med 349:1207-15. 2003..We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone... - Bone densitometry in asymptomatic primary hyperparathyroidismPaul D Miller
University of Colorado Health Sciences Center, Colorado Center for Bone Research, Lakewood 80227, USA
J Bone Miner Res 17:N98-102. 2002 - Update on osteoporosis therapyJoao Lindolfo C Borges
Universidade Catolica de Brasilia, DF, Brazil
Arq Bras Endocrinol Metabol 50:755-63. 2006..Despite the effectiveness of therapy with pharmacologic agents, most patients who start therapy do not remain on treatment for more than 1 year... - Aromatase activity and bone homeostasis in menLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences, and Biochemistry, University of Siena, Siena 53100, Italy
J Clin Endocrinol Metab 89:5898-907. 2004.... - New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imagingPaul Roschger
Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 4th Department, Hanusch Hospital, Vienna, Austria
J Bone Miner Res 22:717-23. 2007..A strong correlation between bone turnover status and degree and heterogeneity of mineralization was found. Further studies are needed before we can draw conclusions about fracture risk in this disorder... - Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugsCarolina A M Kulak
Serviço de Endocrinologia e Metabologia, Hospital de Clinicas, Universidade Federal do Parana, Curitiba, PR, Brazil
Arq Neuropsiquiatr 62:940-8. 2004..38). We conclude that patients on chronic use of AED have alterations in bone metabolism characterized in this study by lower BMD of the lumbar spine and total femur and lower serum concentrations of 25OHD... - Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trialElena Ambrogini
Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy
J Clin Endocrinol Metab 92:3114-21. 2007..It is unclear whether patients with asymptomatic primary hyperparathyroidism (PHPT) do better with parathyroidectomy (PTx) as compared with conservative medical management... - Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapyCarolina A M Kulak
Serviço de Endocrinologia e Metabologia, Hospital de Clinicas, UFPR, Curitiba, PR, Brasil
Arq Bras Endocrinol Metabol 51:466-71. 2007..In conclusion, patients on AED demonstrate reduced BMD. Among the AED, phenobarbital seems to be the main mediator of low BMD and increases in CTX-I... - What's good for the goose's skeleton is good for the gander's skeletonJohn P Bilezikian
J Clin Endocrinol Metab 91:1223-5. 2006 - Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatidePaul D Miller
FACP, Colorado Center for Bone Research, 3190 South Wadsworth, Suite 250, Lakewood, Colorado 80227, USA
J Clin Endocrinol Metab 92:3535-41. 2007..Teriparatide (TPTD) [recombinant human PTH(1-34)] given sc once daily transiently increases serum calcium concentrations at 4-6 h after dosing, but its effects on urinary calcium excretion are less well studied... - Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH studyPatrick Garnero
INSERM Research Unit 664, Lyon, France
J Bone Miner Res 23:1442-8. 2008..The influence of these biochemical changes of type I collagen on bone fracture resistance remains to be studied... - Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidismRuth Zoehrer
Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK Social Health Insurance Vienna, Vienna, Austria
J Clin Endocrinol Metab 93:3484-9. 2008..Hence, there is need to characterize this disorder with particular attention to the skeleton... - Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjectsStefania Bonadonna
Department of Medical Sciences, University of Brescia, Brescia, Italy
Eur J Endocrinol 152:199-205. 2005.... - One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosisDennis M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105, USA
N Engl J Med 353:555-65. 2005..In the continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in bone mineral density after one year of therapy with parathyroid hormone (1-84)... - Reduced bone mineral density is associated with breast arterial calcificationJhansi Reddy
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Clin Endocrinol Metab 93:208-11. 2008..The purpose of this study was to determine the association between reduced bone mineral density (BMD) and BAC, which may share a common pathophysiology... - Mechanisms of anabolic therapies for osteoporosisErnesto Canalis
Department of Research, Saint Francis Hospital and Medical Center, Hartford, CT 06105-1299, USA
N Engl J Med 357:905-16. 2007 - Position statements of the International Society for Clinical Densitometry: methodologyEdward S Leib
J Clin Densitom 5:S5-10. 2002..Details of the methodology used at the conference are discussed. The following papers explain the results of the discussions and describe the official ISCD positions... - Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development ConferenceSanford Baim
Medical College of Wisconsin, Milwaukee, WI, USA
J Clin Densitom 11:75-91. 2008.... - Position Development Conference of the International Society for Clinical Densitometry. Vancouver, BC, July 15-17, 2005Edward S Leib
University of Vermont Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA
J Rheumatol 33:2319-21. 2006..The Official Positions reached at this conference enumerated in this report have been published in The Journal of Clinical Densitometry, and can be found at www.iscd.org... - Bone strength in primary hyperparathyroidismJohn P Bilezikian
Osteoporos Int 14:S113-5; discussion S115-7. 2003..Greater knowledge of the disease should help in understanding anabolic aspects of PTH when it is used as a treatment for osteoporosis...
Research Grants
- TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISMJohn Bilezikian; Fiscal Year: 2007..The majority of trainees go on to careers in investigative endocrinology. The Program focuses upon applicants who hold the M.D. or M.D./Ph.D. degrees and have a strong interest in or prior exposure to investigation. ..
- Targeting Bone Remodeling For the Treatment of OsteoporosisJohn Bilezikian; Fiscal Year: 2007....
- BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTHJohn Bilezikian; Fiscal Year: 2009..This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis. ..
- Treatment of Hypoparathyroidism with Parathyroid HormoneJohn P Bilezikian; Fiscal Year: 2010..This sponsor-investigator expects PTH (1-84) to become the treatment of choice for this orphan disease. ..
- PRIMARY HYPERPARATHYROIDISMJohn Bilezikian; Fiscal Year: 2009..The project is designed to elucidate aspects of this disorder that have been elusive, but which when characterized, will enhance our approach to the therapy of this disorder. ..
- PRIMARY HYPERPARATHYROIDISMJohn P Bilezikian; Fiscal Year: 2010..The project is designed to elucidate aspects of this disorder that have been elusive, but which when characterized, will enhance our approach to the therapy of this disorder. ..
- PRIMARY HYPERPARATHYROIDISMJohn Bilezikian; Fiscal Year: 2001....
- PRIMARY HYPERPARATHYROIDISMJohn Bilezikian; Fiscal Year: 2006..The results should lead to the establishment of rational recommendations for the management of primary hyperparathyroidism. ..
- BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECTS OF PTHJohn P Bilezikian; Fiscal Year: 2010..PUBLIC HEALTH RELEVANCE: This project is designed to gain new knowledge of the means by which parathyroid hormone, a key regulator of skeletal health, helps to keep bones strong. ..